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ABBREVIATIONS 
1L = first-line 
2L = second-line 
3L+ = third- or later line 
AE = adverse event 
BICR = blinded independent central review 
CI = confidence interval 
DOR = duration of response 
ECOG PS = Eastern Cooperative Oncology Group performance status 
FDA = US Food and Drug Administration 
NSCLC = non-small cell lung cancer 
ORR = objective response rate 
OS = overall survival 
PD-1 = programmed death-1 
PD-L1 = programmed death ligand 1 
SCLC = small cell lung cancer 
TMB = tumor mutational burden 
TRAE = treatment-related adverse event  
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ABSTRACT 
Introduction: For patients with recurrent small cell lung cancer (SCLC), topotecan 
remains the only FDA-approved or EMA-approved second-line treatment, and outcomes 
are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or 
nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors 
previously treated with ≥1 platinum-based chemotherapies. We report results of third- or 
later-line (3L+) nivolumab monotherapy treatment in SCLC. 
Methods: In this analysis, patients with limited-stage or extensive-stage SCLC and 
disease progression after ≥2 chemotherapy regimens received nivolumab monotherapy 
3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The primary 
end point was objective response rate (ORR). Secondary end points included duration 
of response (DOR), progression-free survival, overall survival, and safety. 
Results: Between December 4, 2013 and November 30, 2016, 109 patients initiated 
3L+ nivolumab monotherapy. At a median follow-up of 28.3 months (from first dose to 
database lock), ORR was 11.9% (95% confidence interval: 6.5–19.5) with a median 
DOR of 17.9 months (range, 3.0 to 42.1). At 6 months, 17.2% of patients were 
progression-free. The 12-month and 18-month overall survival rates were 28.3% and 
20.0%, respectively. Grade 3–4 treatment-related adverse events (TRAEs) occurred in 
11.9% of patients. Three patients (2.8%) discontinued due to TRAEs. 
Conclusions: Nivolumab monotherapy provided durable responses and was well 
tolerated as a 3L+ treatment for recurrent SCLC. These results suggest that nivolumab 
monotherapy is an effective 3L+ treatment for this patient population. 
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Introduction 
Small cell lung cancer (SCLC) is an aggressive disease with no treatment 
options that produce durable responses.1-3 Current first-line (1L) treatments include 
platinum-based chemotherapy, which have good initial response rates (60% to 80% for 
extensive-stage disease); however, nearly all patients relapse shortly after treatment 
and median survival is only 1 to 2 years from the time of diagnosis.2,4 The only second-
line (2L) therapy for SCLC is topotecan, which was initially approved as an intravenous 
formulation in 1998 and as an oral formulation in 2007. The median duration of 
response (DOR) with intravenous topotecan is 3.3 months,5 and treatment is 
characterized by high rates of grade 4 neutropenia (intravenous, 70%; oral, 32%), grade 
4 thrombocytopenia (intravenous, 29%; oral, 6%), and grade 3–4 anemia (intravenous, 
42%; oral, 25%).6,7  
Nivolumab is a fully human immunoglobulin G4 programmed death (PD)–1 
immune checkpoint inhibitor antibody approved for the treatment of various cancer 
types, including previously treated non-small cell lung cancer (NSCLC).8 Overall survival 
(OS) was significantly prolonged with nivolumab versus docetaxel in a pooled analysis 
of patients with previously treated advanced NSCLC from the phase 3 CheckMate 017 
and 057 trials (pooled hazard ratio = 0.70 [95% confidence interval (CI): 0.61–0.81]).9 In 
a long-term analysis of patients with previously treated advanced NSCLC from the 
phase 1 CA209-003 study, the estimated 5-year OS rate was 16% with nivolumab 
monotherapy.10 On August 16, 2018, nivolumab monotherapy received approval by the 
US Food and Drug Administration (FDA) for the treatment of patients with metastatic 
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SCLC with progression after platinum-based chemotherapy and at least one other line 
of therapy based on results presented in this manuscript. 
CheckMate 032 (ClinicalTrials.gov number, NCT01928394) is a multicenter, 
open-label, phase 1/2 trial evaluating nivolumab alone or in combination with ipilimumab 
in previously treated advanced or metastatic solid tumors. In an interim analysis of this 
study, a manageable safety profile and durable responses were observed with 
nivolumab monotherapy in a nonrandomized cohort of patients with SCLC and ≥1 prior 
platinum-based chemotherapy regimens.11 Here we report the efficacy and safety of 
third- or later-line (3L+) nivolumab monotherapy from pooled nonrandomized and 
randomized cohorts of patients with recurrent SCLC from CheckMate 032.  
 
Patients and Methods 
Study Design and Treatment 
Patients enrolled in CheckMate 032 were assigned to separate cohorts according 
to tumor type. Eligibility criteria for the SCLC cohort of CheckMate 032 included ≥18 
years of age, Eastern Cooperative Oncology Group performance status (ECOG PS) of 
0 or 1, histologically or cytologically confirmed limited-stage or extensive-stage SCLC, 
and previous treatment with one or more platinum-based chemotherapy regimens. The 
current analysis includes patients with disease progression after two or more prior 
chemotherapy regimens. Patients were eligible regardless of platinum sensitivity or 
tumor programmed death ligand 1 (PD-L1) expression. Further eligibility criteria and trial 
details have been previously reported.11 
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Patients with SCLC were initially enrolled as part of a nonrandomized cohort 
(Supplementary Fig. 1), the design of which has been previously described.11 A 
subsequent randomized cohort was added to confirm clinical activity observed in the 
initial phase. The analysis here reports pooled results from the monotherapy arms of the 
nonrandomized and randomized cohorts. In both cohorts, nivolumab monotherapy 3 
mg/kg was administered every 2 weeks until disease progression or unacceptable 
toxicity. Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg was also evaluated in both 
cohorts, the results of which will be reported separately. As previously reported, 
nivolumab 1 mg/kg plus ipilimumab 1 mg/kg and nivolumab 3 mg/kg plus ipilimumab 1 
mg/kg doses were also assessed in the nonrandomized dose-escalation cohort.11 
The primary end point of this study was objective response rate (ORR) by 
blinded independent central review (BICR) assessment per Response Evaluation 
Criteria in Solid Tumors version 1.1.12 DOR by BICR, progression-free survival by BICR, 
OS, and safety were also evaluated as secondary end points. Tumor assessments were 
conducted at baseline, every 6 weeks for the first 24 weeks, and every 12 weeks 
thereafter until disease progression or treatment discontinuation. Survival was 
monitored every 3 months after treatment discontinuation. Safety was evaluated 
throughout the study, and adverse events (AEs) were graded according to the National 
Cancer Institute’s Common Terminology Criteria for Adverse Events version 4.0. 
Tumor PD-L1 expression was assessed retrospectively in pretreatment (archival 
or fresh) tumor biopsy specimens with the use of a validated, automated 
immunohistochemical assay (Dako North America, Carpinteria, CA) using a rabbit anti-
human PD-L1 antibody (clone 28-8; Epitomics Inc, Burlingame, CA).13 Tumor PD-L1 
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expression was categorized as positive when staining of tumor-cell membranes (at any 
intensity) was observed at prespecified expression levels (≥1% of tumor cells in a 
section that included ≥100 evaluable tumor cells). 
The study protocol was approved by an institutional review board or independent 
ethics committee at each participating center. The study was conducted in accordance 
with the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the 
International Conference on Harmonisation. Written informed consent was collected 
from all patients prior to enrollment. BMS policy on data sharing may be found at 
https://www.bms.com/researchers-and-partners/independent-research/data-sharing-
request-process.html. 
Statistical Analysis 
Data included in this analysis were pooled from the nonrandomized and 
randomized cohorts. Analyses for efficacy were conducted as described previously.11 
The safety profile of nivolumab was assessed in all treated patients through summaries 
and by-subject listings of deaths, serious AEs, AEs leading to discontinuation, overall 
AEs, and select AEs. The database lock for this analysis was November 6, 2017. 
 
Results 
Patients and Treatment 
In the pooled SCLC cohort of CheckMate 032, 109 patients (nonrandomized 
cohort, n = 59; randomized cohort, n = 50) initiated 3L+ nivolumab monotherapy 
between December 4, 2013 and November 30, 2016. Baseline patient characteristics 
are presented in Table 1. Briefly, median patient age was 64 years, 92.7% of patients 
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were current or former smokers, and 56.0% were male. Approximately 17% of patients 
with quantifiable PD-L1 had ≥1% tumor PD-L1 expression. The majority (71.6%) of 
patients were treated with two prior systemic treatment regimens; 22.9% were treated 
with three, and 5.5% with four or more prior systemic regimens. Prior platinum-based 
therapies included carboplatin in 67.0% of patients and cisplatin in 56.9% of patients. 
Nearly two-thirds of patients (65.1%) had platinum-sensitive SCLC (defined as 
progression-free ≥90 days after completion of platinum-based chemotherapy) and one-
third (33.9%) had platinum-resistant disease. 
At a minimum follow-up of 11.9 months (median time from first dose to database 
lock, 28.3 months), 8 patients (7.3%) remained on 3L+ nivolumab monotherapy. Among 
patients who did not continue nivolumab monotherapy, the most common reason for 
treatment discontinuation was disease progression (74.3%; Supplementary Table 1). 
The median duration of nivolumab monotherapy was 1.2 months (range, 0.0 to 44.2+; + 
symbol indicates a censored value). 
Efficacy 
 In 109 patients treated with 3L+ nivolumab monotherapy, confirmed ORR was 
11.9% (95% CI: 6.5–19.5; Table 2). The median DOR was 17.9 months (95% CI: 7.9–
42.0; range, 3.0 to 42.1; Fig. 1); DOR was at least 12 months in 61.5% of patients with 
an objective response (Table 2). Response rates were similar across most patient 
subgroups, including patients with <1% and ≥1% tumor PD-L1 expression, with the 
exception of ECOG PS where ORR was higher in patients with an ECOG PS of 0 
versus 1 (21.9% versus 6.6%; Supplementary Table 2). 
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 The median progression-free survival in patients treated with 3L+ nivolumab 
monotherapy was 1.4 months (95% CI: 1.3–1.6), and 17.2% (95% CI: 10.7–25.1) of 
patients were progression-free at 6 months according to Kaplan-Meier estimates (Fig. 
2). The median OS was 5.6 months (95% CI: 3.1–6.8), with a 12-month OS rate of 
28.3% (95% CI: 20.0–37.2) and an 18-month OS rate of 20.0% (95% CI: 12.7–28.6; Fig. 
3). 
Safety 
Any grade and grade 3–4 treatment-related adverse events (TRAEs) with 3L+ 
nivolumab monotherapy were reported in 55.0% and 11.9% of patients, respectively 
(Table 3). Three percent of patients discontinued treatment due to TRAEs, all of which 
were grade 3–4. Most select TRAEs (defined as AEs of potential immunologic causes) 
were grade 1–2 (Supplementary Table 3). The most common select TRAEs of any 
grade were skin reactions (21.1%); the most frequent 3–4 select TRAEs were 
pulmonary events (1.8%; n = 2, both pneumonitis). One treatment-related neurologic AE 
(grade 3–4 encephalitis) was reported. One treatment-related death due to pneumonitis 
was noted. 
 
Discussion 
In this analysis from CheckMate 032, nivolumab monotherapy resulted in an 
objective response by BICR in 11.9% of patients with recurrent limited-stage or 
extensive-stage SCLC previously treated with two or more chemotherapy regimens. 
Patients whose tumors were platinum refractory to 1L therapy were included, and there 
was no selection by biomarker such as tumor PD-L1 expression. Among patients who 
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responded to nivolumab, 61.5% experienced durable DORs lasting at least 1 year 
(median DOR, 17.9 months). Response rates were similar across most patient 
subgroups, with the exception of ECOG PS; ORR was higher in patients with an ECOG 
PS of 0 (21.9%) versus 1 (6.6%). Overall, nivolumab monotherapy was well tolerated, 
with a low (2.8%) discontinuation rate due to TRAEs. These results supported the 
recent FDA approval of nivolumab for the treatment of patients with metastatic SCLC 
that progressed after platinum-based chemotherapy and at least one other line of 
therapy. 
Patients who have received two or more previous lines of therapy for SCLC are 
often symptomatic from progression of cancer, side effects of previous therapy, and 
comorbidities. Choices for such patients in the past have included best supportive care 
with hospice, additional cytotoxic chemotherapy, and clinical trials. The current analysis 
addresses a need for data in patients with SCLC who have progressed following 
multiple lines of therapy. Reports have indicated that approximately 10% to 20% of 
patients who receive 1L chemotherapy will subsequently receive therapy in the 3L 
setting.14-16 The current National Comprehensive Cancer Network guidelines do not 
provide a specific recommendation for 3L+ treatment, but recommend enrollment in 
clinical trials as the preferred option.3 An area of unmet medical need in the 3L+ 
treatment of SCLC is effective therapy that does not add to the side effects of cytotoxic 
chemotherapy. Nivolumab is listed among several other systemic therapy options in the 
National Comprehensive Cancer Network guidelines, consistent with the recent FDA 
approval of nivolumab for the 3L+ treatment of metastatic SCLC. 
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Data supporting 3L+ therapies in patients with SCLC are limited to reports of 
real-world evidence. An international real-world, retrospective analysis evaluating 3L 
chemotherapy treatment in patients with SCLC (N = 120) reported a median OS of 4.7 
months and response rate of 18%; of note, DOR was not reported in this study.17 
However in that study, responses were investigator determined, and the population 
mostly included patients with platinum-sensitive disease who received two different 
platinum-based chemotherapy combination regimens. Therefore, these data cannot be 
directly compared with our analysis. In a recent analysis of a US-based, real-world 
patient cohort matched to the CheckMate 032 population and who received 3L therapy 
for SCLC (n = 92), the 1-year OS rate was 11% (poster to be presented at the World 
Conference on Lung Cancer on September 23–26, 2018 in Toronto, Canada [abstract 
#13791]). Patients in this cohort did not receive 3L immunotherapy treatment, 
highlighting the benefit of nivolumab monotherapy reported in the present CheckMate 
032 analysis (1-year OS rate, 28.3%). The patients evaluated in this study of nivolumab 
were largely representative of the previously treated SCLC population and, to our 
knowledge, represent the largest cohort of patients with recurrent SCLC treated with a 
3L+ immune checkpoint inhibitor. 
Although results from several studies in patients with recurrent SCLC have 
recently been presented, few have reported data specifically in 3L populations. A 
subgroup analysis of the phase 2 TRINITY study in the 3L+ population reported an 
independent review committee–assessed ORR of 16% (28/177) in biomarker-selected 
patients treated with 3L rovalpituzumab tesirine, an antibody-drug conjugate that targets 
Delta Like Canonical Notch Ligand 3 (DLL3).18 The independent review committee–
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assessed DOR in this study was 4.1 months (95% CI: 3.0–4.2). Recently reported 
phase 1/2 studies of immuno-oncology agents included biomarker-unselected patients 
treated with at least one prior line of therapy, with ORRs ranging from 9.5% to 18.7% 
and landmark 1-year OS rates of 28% to 43%.11,19-21 
Ideally, identifying subsets of patients more likely to benefit from treatment with 
nivolumab monotherapy remains an important research goal. Tumor PD-L1 expression 
is a biomarker for response to PD-1 inhibitors in patients with NSCLC22; however, as 
measured using the validated Dako PD-L1 IHC 28-8 pharmDx assay, it did not appear 
to predict response to nivolumab in the present 3L+ analysis of CheckMate 032, or in an 
interim analysis of the 2L+ nonrandomized cohort of this study.11 Emerging exploratory 
data from the KEYNOTE-158 study, which uses the combined positive score assay 
(includes tumor cells and intercalating immune cells that stain positive for PD-L1), 
suggests a potential role for PD-L1 expression in selecting patients with SCLC who may 
respond to PD-1 inhibitors.20 
Tumor mutational burden (TMB) is also emerging as an independent biomarker 
of response to immune checkpoint inhibitors in various cancer types, including SCLC, 
NSCLC, bladder cancer, and melanoma.23-33 In a separate analysis of the pooled 
nivolumab monotherapy cohort in CheckMate 032, ORR was 21.3% in patients with 
high TMB (≥248 mutations by whole exome sequencing) versus 4.8% in those with low 
TMB (0 to <143 mutations).25 Future prospective evaluations of nivolumab monotherapy 
in a TMB-selected population with SCLC may help identify patients more likely to 
respond. 
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Patients with SCLC who have progressed on multiple lines of treatment have few 
therapeutic options in the 3L and beyond. Best supportive care, often including hospice, 
is the best choice for some patients in this setting. Clinical trials remain an important 
option in previously treated SCLC. Here we show that clinically meaningful results are 
achievable with nivolumab monotherapy in a population with biomarker-unselected 
SCLC and ECOG PS ≤1, including patients with platinum-refractory disease. 
Responses to nivolumab are durable in the minority of patients who respond, with a 
tolerable safety profile. For patients who have received multiple lines of therapy for 
metastatic SCLC, nivolumab may provide an additional treatment option. Furthermore, 
these data warrant further investigation of immuno-oncology approaches in SCLC. 
Additional analyses of the randomized SCLC cohort of CheckMate 032, including 
patients treated with the combination of nivolumab plus ipilimumab, are underway and 
will be published separately. Phase 3 studies evaluating nivolumab alone and in 
combination with ipilimumab for SCLC as maintenance treatment after induction therapy 
(ClinicalTrials.gov number, NCT02538666) and nivolumab monotherapy for SCLC in the 
2L setting (ClinicalTrials.gov number, NCT02481830) are ongoing. 
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FIGURE LEGENDS 
 
Figure 1. DOR by blinded independent central review with 3L+ nivolumab monotherapy. 
3L+, third- or later line; CI, confidence interval; DOR, duration of response. 
 
Figure 2. PFS by blinded independent central review with 3L+ nivolumab monotherapy. 
3L+, third- or later line; CI, confidence interval; PFS, progression-free survival. 
 
Figure 3. OS with 3L+ nivolumab monotherapy. 3L+, third- or later line; CI, confidence 
interval; OS, overall survival.  
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TABLES 
Table 1. Baseline Characteristics in Patients Treated With 3L+ Nivolumab Monotherapy 
 3L+ Nivolumab (n = 109) 
Median (range) age, y 64.0 (45–81) 
≥75 years, n (%) 7 (6.4) 
Male, n (%) 61 (56.0) 
Race, n (%)  
White 102 (93.6) 
Black/African American 4 (3.7) 
Other 3 (2.8) 
Prior systemic treatment regimens, n (%)  
2 78 (71.6) 
3 25 (22.9) 
>3 6 (5.5) 
First-line platinum-treated patients, n (%)  
Platinum-sensitivea 71 (65.1) 
Platinum-resistantb 37 (33.9) 
Unknown 1 (0.9) 
Smoking status, n (%)  
Current/former smoker 101 (92.7) 
Never smoker 8 (7.3) 
ECOG PS, n (%)  
0 32 (29.4) 
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1 76 (69.7) 
2c 1 (0.9) 
Tumor PD-L1 expression, n (%)  
<1% 65 (59.6) 
≥1% 13 (11.9) 
Not quantifiabled 31 (28.4) 
aProgression-free ≥90 days after completion of platinum-based chemotherapy. 
bProgression-free <90 days after completion of platinum-based chemotherapy. 
cPatients with an ECOG PS score ≥2 were not eligible for inclusion in this study. The 
patient who had an ECOG PS of 2 at baseline had a PS of 1 at screening and a PS of 2 
at the first dosing date 15 days later. 
dNot evaluable, indeterminate, or missing. 
3L+, third- or later line; ECOG PS, Eastern Cooperative Oncology Group performance 
status; PD-L1, programmed death ligand 1. 
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Table 2. ORRs With 3L+ Nivolumab Monotherapy  
 3L+ Nivolumab (n = 109) 
ORR by BICRa  
No. of patients 13 
% of patients (95% CI) 11.9 (6.5–19.5) 
Best overall response, n (%)  
Complete response 1 (0.9) 
Partial response 12 (11.0) 
Stable disease 25 (22.9) 
Progressive disease 56 (51.4) 
Unable to determine 14 (12.8) 
Not reported 1 (0.9) 
Median time to response, months 1.6 
Duration of response  
≥6 months, n (%) 10 (76.9) 
≥12 months, n (%) 8 (61.5) 
Median (95% CI), monthsb 17.9 (7.9–42.0) 
Range, months 3.0–42.1 
aPer Response Evaluation Criteria in Solid Tumors v1.1. 
bComputed using Kaplan-Meier method. 
3L+, third- or later line; BICR, blinded independent central review; CI, confidence 
interval; ORR, objective response rate. 
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Table 3. Treatment-Related Adverse Events 
Event, n (%) 3L+ Nivolumab (n = 109) 
Any Grade Grade 3–4 
Any event 60 (55.0) 13 (11.9) 
Any serious event 9 (8.3) 8 (7.3) 
Any event leading to discontinuation 3 (2.8) 3 (2.8) 
Most frequent events (≥5%)   
Pruritus 14 (12.8) 0 
Fatigue 11 (10.1) 1 (0.9) 
Nausea 8 (7.3) 0 
Rash 7 (6.4) 1 (0.9) 
Diarrhea 7 (6.4) 0 
Decreased appetite 6 (5.5) 1 (0.9) 
Data are based on a November 6, 2017 database lock. Safety analysis included all 
patients who received at least one dose of study drug. Includes events reported from 
the time of the first dose of study drug to 30 days after the last dose. 
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